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Abstract
Purpose Cholecystokinin 2 (CCK-2) receptor overexpression
has been demonstrated in various tumours such as medullary
thyroid carcinomas and small-cell lung cancers. Due to this
high expression, CCK-2 receptors might be suitable targets
for radionuclide imaging and/or radionuclide therapy. Several
CCK-2 receptor-binding radiopeptides have been developed
and some have been tested in patients. Here we aimed to
compare the in vivo tumour targeting properties of 12 111In-
labelled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid (DOTA)-conjugated gastrin/CCK2 receptor-binding
peptides.
Methods Two CCK8-based peptides and ten gastrin-based
peptide analogues were tested. All peptides were conjugat-
ed with DOTA and labelled with 111In. Biodistribution
studies were performed in mice with subcutaneous CCK2/
gastrin receptor-expressing tumours and with receptor-
negative tumours contralaterally. Biodistribution was stud-
ied by counting dissected tissues at 1 and 4 h after injection.
Results Both the CCK analogues displayed relatively low
tumour uptake (approximately 2.5%ID/g) as compared to
minigastrin analogues. Two linear minigastrin peptides
(MG0 and sargastrin) displayed moderate tumour uptake
at both 1 and 4 h after injection, but also very high kidney
uptake (both higher than 48%ID/g). The linear MG11,
lacking the penta-Glu sequence, showed lower tumour
uptake and also low kidney uptake. Varying the N-terminal
Glu residues in the minigastrin analogues led to improved
tumour targeting properties, with PP-F11 displaying the
optimal biodistribution. Besides the monomeric linear
peptides, a cyclized peptide and a divalent peptide were
tested.
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Conclusion Based on these studies, optimal peptides for
peptide receptor radionuclide targeting of CCK2/gastrin
receptor-expressing tumours were the linear minigastrin ana-
logue with six D-Glu residues (PP-F11), the divalent analogue
MGD5 and the cyclic peptide cyclo-MG1. These peptides
combined high tumour uptake with low kidney retention, and
may therefore be good candidates for future clinical studies.
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Introduction
Cholecystokinin 2 (CCK-2) receptor overexpression has
been demonstrated in a high percentage of various tumours
such as medullary thyroid carcinomas (>90%) and small-
cell lung cancer (89%) [1]. Due to this high expression,
CCK-2 receptors might be suitable targets for radionuclide
imaging and/or radionuclide therapy.
The peptides of the gastrin and CCK family are
characterized by an amidated C-terminal receptor binding
sequence Trp-Met-Asp-Phe-NH2. Gastrin peptides have a
pentaglutamic acid sequence, which is absent in the CCK
peptides. In addition, both groups of peptides differ by the
location of their tyrosyl residue in relation to the receptor
binding sequence. Peptides of the gastrin family have one
amino acid (usually Gly), and peptides of the CCK family
have two amino acids (Met-Gly or Thr-Gly) between this
Tyr moiety and the receptor binding sequence. In CCK
analogues, this Tyr residue plays a role in the receptor
specificity. When this Tyr residue is sulphated, the peptides
display high affinity for both the CCK1 and the CCK2
receptor (8 nM and 3 nM, respectively). In contrast, the
nonsulphated peptides show a 1,000-fold lower affinity for
the CCK1 receptor than for the CCK2 receptor [2].
Aloj et al. [3] studied tumour targeting of glycine
extended nonsulphated CCK8. As sulphation of the Tyr
residue leads to enhanced tumour targeting [4], based on
sulphated CCK8, sCCK8[Phe2(p-CH2SO3H),HPG
3,6]
(SA106) has been developed. In this peptide two Met
residues are replaced by homopropargyl glycine to prevent
oxidation of these amino acids, which are required for
receptor binding [5]. Whereas the CCK analogues generally
display moderate tumour uptake and low kidney accumu-
lation, the gastrin analogues show a much better tumour
uptake, but this is accompanied by a high kidney uptake.
When using these radiolabelled peptides for peptide
receptor radionuclide therapy, the high kidney uptake is
undesirable. This will lead to a high radiation dose to the
kidneys, thus hampering radionuclide therapy.
Marsouvanidis et al. developed a DOTA-conjugated
analogue of human gastrin-17, called sargastrin [6]. To
optimize in vivo characteristics, Good et al. synthesized N-
terminally truncated versions of the gastrin peptide. Mini-
gastrin 0 (MG0) is a 12 amino acid peptide with a
macrocyclic chelator coupled N-terminally via a D-Glu
residue. In MG11, the pentaglutamic acid sequence has
been deleted yielding an octapeptide with much lower
kidney uptake [7] . Based on these data it was hypothesized
that the negative charge of the pentaglutamic acid sequence
is responsible for the high kidney retention. Therefore, in an
attempt to decrease the kidney uptake, in PP-F10 the Glu
residues were replaced by D-Gln residues. In addition, in
PP-F11, the pentaglutamic acid sequence has been replaced
by five D-glutamic acid residues yielding a hexa D-Glu
sequence. Furthermore, PP-F16 was synthesized with three
D-Gln and three D-Glu residues alternately. Finally, PP-F6
was synthesized with only three D-Gln residues. Based on
MG11, the peptide APH070 has been synthesized [8]. This
peptide has two additional histidyl residues N-terminally,
yielding a better tumour-to-kidney ratio than the parent
MG11. In an attempt to increase receptor affinity and
tumour uptake, Sosabowski et al. [9] synthesized a DOTA-
conjugated divalent minigastrin (MGD5) that demonstrates
improved tumour targeting compared to the monomeric
form of the peptide (APH070). In another approach von
Guggenberg et al. used a cyclic form of minigastrin (cyclo-
MG1) and labelled it with 99mTc for imaging of CCK2/
gastrin receptor-expressing tumours [10].
In vitro and in vivo characteristics of some of these
peptides have been described before. The present study,
however, is the first side-by-side comparison of their
biodistribution in tumour-bearing mice.
Materials and methods
Peptides
All peptides were synthesized using standard Fmoc-based
solid-phase peptide synthesis and conjugated with 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), using
one of the carboxylic groups of DOTA. No linkers between
DOTA and peptide were used. All peptide structures were
confirmed by mass spectrometry and NMR. Peptides were
dissolved in appropriate buffers. Table 1 lists the names, amino
acid sequences and molecular weights of the peptides. All
buffers used for the radiolabelling procedures were metal-free.
Metal-free buffers were obtained by treatment with Chelex-
100 resin (BioRad, Hercules, CA) and subsequent filtration
through a 0.22-μm filter.
Radiolabelling
DOTA-conjugated peptides were radiolabelled with 111In by
incubation with 111InCl3 (Covidien, Petten, The Netherlands)
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in 0.25 M ammonium acetate buffer, pH 5.0. To prevent
oxidation of the peptides during radiolabelling, 100 μg
(10 μl) selenomethionine was added. The labelling mixture
was incubated for 30 min at 95°C. After incubation, 50 mM
EDTA was added to a final concentration of 5 mM.
Radiochemical purity and the presence of oxidized peptide
was checked on an HPLC system (1200 series LC system;
Agilent Technologies, Palo Alto, CA) equipped with an
Alltima RP-C18 column (5 μm, 4.6×250 mm; Alltech,
Deerfield, IL) and an in-line NaI radiodetector (Raytest,
Straubenhardt, Germany). A gradient from 0.1% trifluoro-
acetic acid in water to 0.1% trifluoroacetic acid in
acetonitrile was used. The specific activity of all peptides
was 11 GBq/μmol and radiochemical purity was always
higher than 95%.
Cell culture
Two transfected human epidermoid carcinoma cell lines
(A431) were used. Stably transfected cells were constructed
as described previously [3]. Cell lines were stably transfected
with cDNA encoding for CCK2R or with empty vector
(‘mock-transfected’). Cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Gibco Life Technolo-
gies, Gaithersburg, MD) supplemented with 4,500 mg/l D-
glucose, 10% (v/v) fetal calf serum, 2 mmol/l glutamine and
250 μg/ml G418. Cells were cultured at 37°C in a
humidified atmosphere containing 5% CO2.
Biodistribution studies
Tumour targeting of the 111In-labelled peptides was studied in
female athymic BALB/c mice with subcutaneous tumours
induced by inoculation of CCK2 receptor-transfected and
mock-transfected A431 cells. Mice were inoculated with 2×
106 A431-CCK2R cells (0.2 ml) in the left flank and with
A431 mock-transfected cells in the right flank. After
approximately 10 days, when the tumours had reached a
weight of approximately 0.1–0.2 g, the mice were randomly
divided into groups of five mice. The mice were injected
intravenously with 370 kBq (0.03 nmol) of 111In-labelled
peptide via the lateral tail vein. In addition, one group of
mice was injected with a 1,000-fold molar excess of the
same unlabelled peptide to determine the non-CCK2R-
mediated uptake in CCK2R-expressing tissues. Mice were
killed by CO2 asphyxiation at 1 and 4 h post-injection (p.i.).
The group injected with an excess of unlabelled peptide was
dissected at 4 h p.i. A blood sample was drawn and organs
of interest and the tumour were dissected, weighed and
counted in a gamma counter. The animal experiments were
approved by the local animal welfare committee and
performed according to national regulations.
Statistical analysis
All mean values are given ± standard deviation (SD).
Statistical analysis was performed using a Welch’s cor-
rected unpaired Student’s t-test or one-way analysis of
variance using StatMate software (version 2.00, GraphPad
Software). The level of significance was set at P<0.05.
Results
Two CCK8 analogues were evaluated. DOTA-conjugated
nonsulphated CCK8 (G-CCK8) displayed moderate tumour
uptake (2.44±1.45%ID/g at 4 h p.i.) with low uptake in
nontarget tissues including the kidneys (Fig. 1). A
stabilized form of sulphated CCK8 (sCCK8[Phe2(p-
CH2SO3H),HPG
3,6], SA106) showed moderate tumour
Table 1 Amino acid sequences of the peptides
Name Sequence MW (g/mol) Reference
G-CCK8 DOTA-Gly-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2 1,507.0 [3]
SA106 DOTA-DAsp-Phe(p-CH2SO3H)-HPG-Gly-Trp-HPG-Asp-Phe-NH2 1,482.6 [5]
MG0 DOTA-DGlu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2,037.0 [7]
Sargastrin DOTA-Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2 2,483.6 –
MG11 DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 1,531.0 [7]
APH070 DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 1,677.8 [8]
PP-F10 DOTA-DGln-DGln-DGln-DGln-DGln-DGln-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2,042.9 –
PP-F6 DOTA-DGln-DGln-DGln-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 1,658.7 –
PP-F16 DOTA-DGln-DGlu-DGln-DGlu-DGln-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2,045.9 –
PP-F11 DOTA-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2,048.8 –
Cyclo-MG1 DOTA-DGlu-(Ala-Tyr)-DLys-Trp-Met-Asp-Phe-NH2 (cyclo DGlu-DLys) 1,455.7 [10]
MGD5 DOTA-Gly-Ser-Cys-(Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2)2 2,782.9 [9]
HPG homopropargyl glycine
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localization (2.65±0.59%ID/g at 4 h p.i.) and specific
accumulation in the pancreas (1.82±0.27%ID/g at 4 h p.i.).
Uptake in all other organs was low.
Ten gastrin-based analogues were included in these
studies. Overall, these peptides had a higher uptake in
CCK2R-expressing tumours than the CCK analogues. The
largest peptide, sargastrin, displayed a high tumour uptake
(11.8±3.1%ID/g and 9.83±4.3%ID/g, 1 and 4 h p.i.,
respectively), but also showed very high uptake in the kidneys
(57.2±3.4 and 60.3±4.8%ID/g, 1 and 4 h p.i., respectively).
The N-terminally truncated gastrin peptide MG0 also showed
high tumour uptake (13.3±4.9%ID/g and 9.9±2.0%ID/g, 1 and
4 h p.i., respectively), but the retention in the kidneys showed a
similarly high level as that of sargastrin (Fig. 1). MG11
(lacking the penta-Glu sequence) displayed a strongly reduced
kidney uptake (0.91±0.14%ID/g at 1 h p.i.), but also tumour
uptake was reduced to only one-third of that of sargastrin and
MG0 (3.04±1.30%ID/g at 1 h p.i.). In APH070, two His
Fig. 1 Tissue distribution of 111In-labelled peptides in mice (n=5/
group) with subcutaneous A431-CCK2R and A431 negative control
tumours at 1 and 4 h p.i. Uptake of radioactivity is expressed as
percentage of the injected dose per gram (%ID/g). Kidney uptake of
MG0 and sargastrin (centre) is truncated to allow comparison with
other peptides. Error bars represent standard deviation
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residues were attached N-terminally to the MG0 sequence [8].
Although displaying low kidney uptake, tumour uptake was
also moderate and comparable to that of MG11.
A series of MG0 analogues were synthesized with
varying sequences of N-terminal amino acids. Peptide PP-
F6 consists of the seven amino acid C-terminal sequence of
gastrin with three D-Gln residues added N-terminally and
PP-F10 was elongated with six D-Gln residues. Both
peptides showed very low kidney uptake (both ≤ 1%ID/g
at 1 h p.i.), but only moderate tumour uptake (1.93±0.37
and 2.31±0.64%ID/g, PP-F6 and PP-F10, respectively, 4 h
p.i.). Substituting the six N-terminal residues by D-Glu
resulted in a favourable biodistribution with high tumour
uptake and retention (9.66±1.78 and 6.30±2.75%ID/g, 1
and 4 h p.i.) accompanied by low kidney retention. The
sequence of this peptide is identical to that of MG0, but the
Fig. 1 (continued)
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N-terminal L-Glu residues have been replaced by their D-
isomers. While maintaining tumour accumulation, kidney
retention was only one-tenth that of MG0, resulting in a
high tumour-to-blood ratio (448±210) and tumour-to-
kidney ratio (1.2±0.5) at 4 h p.i. (Fig. 2). The analogue
with the hexaamino acid sequence with alternating D-Glu
and D-Gln residues (PP-F16) displayed only moderate
tumour uptake (5.56±3.20%ID/g at 1 h p.i.).
Since multimerization has been shown to be an effective
approach to increasing stability and affinity [11], the mini-
gastrin sequence was dimerized using Cys, and in addition the
Met residue was replaced by Nle to prevent oxidation [9].
These changes (MGD5) led to improved tumour accumulation
but also to higher uptake in other organs, including the kidney.
In an attempt to improve the in vivo characteristics, a
cyclized analogue based on MG11, cyclo-MG1, has been
synthesized and tested. Indeed, tumour targeting of cyclo-
MG1 was high (9.88±1.99%ID/g at 1 h p.i.) and kidney
accumulation was low (2.75±0.11%ID/g at 1 h p.i.). Tumour
uptake at 4 h p.i. suggested that tumour retention of this
peptide was impaired since uptake at 4 h p.i. was more than
40% lower (5.76±0.71%ID/g) than at 1 h p.i. (p=0.0067).
Discussion
During the past decade, a wide series of CCK/gastrin
analogues have been produced and tested in vitro and in
vivo. Here we compared the biodistribution of 12 CCK2/
gastrin receptor targeting peptides in mice with CCK2R-
expressing tumours. Ten of these peptides were gastrin
analogues, and two peptides were CCK8 derivatives. The
CCK8 analogues showed lower tumour uptake accompa-
nied by a low kidney retention. The sulphated peptide
sCCK8[Phe2(p-CH2SO3H),HPG
3,6] (SA106) also showed
affinity for the CCK1 receptor, resulting in specific
accumulation in murine pancreas [4]. Specific uptake in
the murine pancreas was not observed for the DOTA-CCK8
peptide (G-CCK8).
From the gastrin analogues, 111In-labelled MG0 and
111In-labelled sargastrin showed the highest kidney accu-
mulation. This uptake was blocked by the coinjection of
agents such as albumin fragments or gelatin-based plasma
expanders [12]. In addition, Béhé et al. showed efficient
blocking of the kidney uptake of 111In-MG0 by using poly-
Glu chains of various lengths [13]. In particular, oligo-Glu
chains of more than five amino acids showed effective
reduction in kidney accumulation. These data suggest that
the high kidney retention is a result of the presence of five
Glu residues. Indeed, reducing the number of Glu residues
in MG0 resulted in a strong reduction of kidney uptake
(MG11), but led to reduced tumour localization of only
one-third of the uptake of MG0. It has been reported that
MG11 is unstable in serum [7], indicating that the penta-
Glu sequence may be responsible for in vivo stability and
kidney uptake. To diminish kidney retention of the gastrin
analogues, four peptides were developed with various N-
terminal sequences consisting of D-Glu and/or D-Gln
residues. Except for these residues, peptide sequences were
similar to those of MG0. Remarkably, replacing the five L-
Glu residues of MG0 by five D-Glu, the new analogue PP-
F11 showed markedly reduced kidney retention (90%
reduced) as compared to that of MG0, while maintaining
high tumour uptake. Replacement by six D-Gln residues
PP-F10 even further reduced kidney uptake, at the cost of
uptake in the tumour. Tumour uptake was further reduced
when using only three D-Gln residues.
Fig. 2 Tumour-to-blood and tumour-to-kidney ratios of 111In-labelled
peptides in A431-CCK2R tumours in mice (n=5/group) at 1 and 4 h p.i
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To further investigate the potential of a shortened gastrin
analogue, Mather et al. screened a series of peptides [8] of
which the peptide with two N-terminal His residues was
selected for further studies. This peptide, APH070, combined
improved stability with moderate tumour uptake, and although
kidney uptake was very low, tumour-to-kidney ratios were
lower as compared to several other gastrin analogues (Fig. 2).
The divalent MGD5 displayed good tumour uptake and
retention, but showed high background levels in all organs.
Blood levels at 1 h p.i. were generally tenfold higher than
those of the other peptides investigated. These high
background levels, most likely caused by the relatively
high blood levels, are in disagreement with previous data
[9] where background levels were three- to fivefold lower.
This could be due to the fact that the present study was
carried out in BALB/c nude mice, while the peptide was
previously tested in CD1 (SCID) mice.
Previously, von Guggenberg et al. reported on the
development of two 99mTc-labelled cyclic minigastrin deriv-
atives [10]. Based on HYNIC-cyclo-MG1, the DOTA-
conjugated form of this peptide was tested. This peptide
combined high tumour accumulation with relatively low
kidney retention, resulting in high tumour-to-blood ratios
and good tumour-to-kidney ratios. Uptake in all other
organs, including the stomach, was the lowest of all peptides
studied. Whereas the 99mTc compound showed good tumour
retention at 1 and 4 h p.i. [10], the 111In-labelled DOTA
cyclo-MG1 showed a more than 40% decrease in tumour
retention between 1 and 4 h p.i.. Except for cyclo-MG1 and
PP-F10, all other peptides showed good tumour retention of
the radioactivity. The methods discussed above aimed to
improve stability and affinity of the peptides. As described in
another paper (Aloj et al., this issue), the affinity of all these
12 peptides was in the same low nanomolar range.
In summary, the highest tumour uptake was obtained
with cyclo-MG1 (9.2±1.0%ID/g), PP-F11 (9.7±1.8%ID/g),
MGD5 (8.9±2.3%ID/g), sargastrin (11.8±3.1%ID/g) and
MG0 (13.3±4.9%ID/g). Of these compounds, sargastrin
and MG0 suffered from high kidney uptake. Tumour
retention of the cyclic peptide was lower than that of the
other peptides. Tumour retention of the divalent peptide
was stable between 1 and 4 h p.i.. In general, tumour-to-
blood and tumour-to-kidney ratios of the CCK analogues
were lower than those of the gastrin analogues.
Conclusion
Based on these studies, optimal peptides for peptide receptor
radionuclide targeting of CCK2/gastrin receptor-expressing
tumours were the linear minigastrin analogue with six D-Glu
residues (PP-F11), the divalent analogue MGD5 and the
cyclic peptide cyclo-MG1. These peptides combined high
tumour uptake with low kidney retention, and may therefore
be good candidates for future clinical studies.
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